Core--cell, tissue and animal facility
核心——细胞、组织和动物设施
基本信息
- 批准号:6565161
- 负责人:
- 金额:$ 26.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2002-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Provided by applicant): The purpose of this core is to assist in
the design of adjunctive therapeutic strategies for treatment and/or
prevention of neurologic disease following human immunodeficiency virus
type-one (HIV-1) infection. In this regard, purified human monocyte-derived
macrophages (MDM) and MDM conditioned media (MCM) will be supplied, following
HIV-1 infection and/or immune activation, to all investigators on request,
within the Rochester Cooperative NeuroAIDS Drug Discovery Group (RCNDDG). In
addition, promising anti-inflammatory and/or neuroprotective drugs, developed
in laboratory assays or proposed, will be tested for therapeutic efficacy in a
severe combined immune deficiency (SCID) mouse model of HIV-1 encephalitis
(HIVE). Brain tissue and/or sera will be made available for measuring drug
levels and pathology in the HIVE mice. Such works will support translational
(bench to bedside) research efforts and directly effect the performance of
subsequent clinical trials. The works, in toto, are based on the concept that
HIV-1 associated dementia (HAD) is, in part, a reversible metabolic
encephalopathy caused by defective immunity of virus-infected mononuclear
phagocytes [(MP), microglia, perivascular and parenchymal macrophages]. These
MPs serve both as reservoirs for productive HIV-1 infection and principal
sources of neurotoxic activities within the central nervous system (CNS). The
development of ways to inhibit toxic inflammatory activities in brain may
serve to both ameliorate and prevent complications of persistent viral
replication in brain serving as critical adjunctive therapies to ongoing
potent anti-retroviral regimens, the principal goals of the RCNDDG.
描述:(由申请人提供):本核心的目的是协助
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Howard E Gendelman其他文献
HIV-1 hijacks tunneling nanotubes and secretory microvesicles for intercellular spread in monocyte-derived macrophages
- DOI:
10.1186/1742-4690-6-s2-o22 - 发表时间:
2009-09-24 - 期刊:
- 影响因子:3.900
- 作者:
Irena Kadiu;Jan M Orenstein;Howard E Gendelman - 通讯作者:
Howard E Gendelman
Howard E Gendelman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Howard E Gendelman', 18)}}的其他基金
HIV-1DetectionandEliminationFrom CNS Mononuclear Phagocytes
CNS 单核吞噬细胞中 HIV-1 的检测和消除
- 批准号:
10645139 - 财政年份:2021
- 资助金额:
$ 26.66万 - 项目类别:
HIV-1DetectionandEliminationFrom CNS Mononuclear Phagocytes
CNS 单核吞噬细胞中 HIV-1 的检测和消除
- 批准号:
10454408 - 财政年份:2021
- 资助金额:
$ 26.66万 - 项目类别:
HIV-1 Detection and Elimination From CNS Mononuclear Phagocytes
CNS 单核吞噬细胞中 HIV-1 的检测和消除
- 批准号:
10327550 - 财政年份:2021
- 资助金额:
$ 26.66万 - 项目类别:
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1
用于消除 HIV-1 的联合分子切除疗法 (CMET)
- 批准号:
10217975 - 财政年份:2017
- 资助金额:
$ 26.66万 - 项目类别:
Glutaminase and its neurotoxic link to HAND
谷氨酰胺酶及其与 HAND 的神经毒性联系
- 批准号:
9700732 - 财政年份:2016
- 资助金额:
$ 26.66万 - 项目类别:
相似海外基金
Renovation of Temple's Psychology Department Animal Colony
天普心理系动物群改造
- 批准号:
9602717 - 财政年份:1997
- 资助金额:
$ 26.66万 - 项目类别:
Standard Grant